ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
21.74
-0.83 (-3.68%)
At close: Apr 10, 2026, 4:00 PM EDT
21.72
-0.02 (-0.09%)
After-hours: Apr 10, 2026, 6:48 PM EDT
ACADIA Pharmaceuticals Revenue
In the year 2025, ACADIA Pharmaceuticals had annual revenue of $1.07B with 11.87% growth. ACADIA Pharmaceuticals had revenue of $283.99M in the quarter ending December 31, 2025, with 9.39% growth.
Revenue (ttm)
$1.07B
Revenue Growth
+11.87%
P/S Ratio
3.46
Revenue / Employee
$1,342,738
Employees
798
Market Cap
3.71B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.07B | 113.71M | 11.87% |
| Dec 31, 2024 | 957.80M | 231.36M | 31.85% |
| Dec 31, 2023 | 726.44M | 209.20M | 40.45% |
| Dec 31, 2022 | 517.24M | 33.09M | 6.83% |
| Dec 31, 2021 | 484.15M | 42.39M | 9.60% |
| Dec 31, 2020 | 441.76M | 102.68M | 30.28% |
| Dec 31, 2019 | 339.08M | 115.27M | 51.50% |
| Dec 31, 2018 | 223.81M | 98.91M | 79.19% |
| Dec 31, 2017 | 124.90M | 107.57M | 620.68% |
| Dec 31, 2016 | 17.33M | 17.27M | 28,311.48% |
| Dec 31, 2015 | 61.00K | -59.00K | -49.17% |
| Dec 31, 2014 | 120.00K | -1.03M | -89.52% |
| Dec 31, 2013 | 1.15M | -3.76M | -76.67% |
| Dec 31, 2012 | 4.91M | 2.84M | 137.40% |
| Dec 31, 2011 | 2.07M | -40.07M | -95.09% |
| Dec 31, 2010 | 42.14M | 35.74M | 558.46% |
| Dec 31, 2009 | 6.40M | 4.81M | 302.45% |
| Dec 31, 2008 | 1.59M | -5.97M | -78.95% |
| Dec 31, 2007 | 7.56M | -578.00K | -7.11% |
| Dec 31, 2006 | 8.13M | -2.82M | -25.77% |
| Dec 31, 2005 | 10.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.03B |
| Telix Pharmaceuticals | 803.79M |
| Corcept Therapeutics | 761.41M |
| Amicus Therapeutics | 634.21M |
| Ligand Pharmaceuticals | 268.09M |
| NewAmsterdam Pharma Company | 22.50M |
| Crinetics Pharmaceuticals | 7.70M |
ACAD News
- 4 days ago - Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome - Business Wire
- 4 weeks ago - Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - Business Wire
- 5 weeks ago - Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - Business Wire
- 6 weeks ago - Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview - Business Wire
- 6 weeks ago - Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences - Business Wire
- 2 months ago - Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 - Business Wire
- 2 months ago - Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union - Business Wire